Phaseline

Targets › IMP3

IMP3 (U3 small nucleolar ribonucleoprotein protein IMP3): drug programs, companies and trials

2 programs from 1 company in 5 trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Component of the 60-80S U3 small nucleolar ribonucleoprotein (U3 snoRNP). Required for the early cleavages during pre-18S ribosomal RNA processing. (UniProt, Q9NV31)

Open in Phaseline: the race on IMP3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
West China HospitalEngineered Mitochondrial Vaccine (IMP3-Mito)
IMP3-targeting vaccine utilizing engineered mitochondrial platform
IMP3Phase 2Head and Neck Squamous Cell Carcinoma; Advanced Solid Tumor MalignanciesDec 2026
West China HospitalIMP3-saRNA (YMN-136) Vaccine
Self-amplifying RNA vaccine targeting IMP3
IMP3Phase 1Liver Cancer; Non-Small Cell Lung Cancer; Colorectal CancerFeb 2028

Conditions

Liver Cancer (1) Non-Small Cell Lung Cancer (1) Colorectal Cancer (1) Head and Neck Squamous Cell Carcinoma (1) Advanced Solid Tumor Malignancies (1)

Modalities

other (1), mixed (1)

Companies

West China Hospital (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.